MCL coexpression mm9:1287
From FANTOM5_SSTAR
Phase1 CAGE Peaks
| Short description | |
|---|---|
| Mm9::chr11:48805759..48805781,- | p3@Tgtp1 p3@Tgtp2 |
| Mm9::chr2:167766298..167766302,+ | p@chr2:167766298..167766302 + |
| Mm9::chr4:149075690..149075711,- | p2@Pik3cd |
| Mm9::chr5:122683421..122683445,+ | p@chr5:122683421..122683445 + |
| Mm9::chr8:90812977..90812990,+ | p8@Adcy7 |
| Mm9::chrX:50113602..50113611,+ | p@chrX:50113602..50113611 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
| GO ID | GO name | FDR corrected p-value |
|---|---|---|
| GO:0019932 | second-messenger-mediated signaling | 0.0041889307110198 |
| GO:0046934 | phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 0.0101825686755877 |
| GO:0046854 | phosphoinositide phosphorylation | 0.0101825686755877 |
| GO:0035004 | phosphoinositide 3-kinase activity | 0.0101825686755877 |
| GO:0016303 | 1-phosphatidylinositol-3-kinase activity | 0.0101825686755877 |
| GO:0005942 | phosphoinositide 3-kinase complex | 0.0101825686755877 |
| GO:0001782 | B cell homeostasis | 0.0101825686755877 |
| GO:0046834 | lipid phosphorylation | 0.0101825686755877 |
| GO:0004016 | adenylate cyclase activity | 0.0101825686755877 |
| GO:0007190 | adenylate cyclase activation | 0.0101825686755877 |
| GO:0031281 | positive regulation of cyclase activity | 0.0101825686755877 |
| GO:0051349 | positive regulation of lyase activity | 0.0101825686755877 |
| GO:0045762 | positive regulation of adenylate cyclase activity | 0.0101825686755877 |
| GO:0045761 | regulation of adenylate cyclase activity | 0.0101825686755877 |
| GO:0006171 | cAMP biosynthetic process | 0.0101825686755877 |
| GO:0031279 | regulation of cyclase activity | 0.0101825686755877 |
| GO:0051339 | regulation of lyase activity | 0.0101825686755877 |
| GO:0002260 | lymphocyte homeostasis | 0.0101825686755877 |
| GO:0046058 | cAMP metabolic process | 0.0101825686755877 |
| GO:0001727 | lipid kinase activity | 0.0101825686755877 |
| GO:0009975 | cyclase activity | 0.0101825686755877 |
| GO:0016849 | phosphorus-oxygen lyase activity | 0.0101825686755877 |
| GO:0030258 | lipid modification | 0.0101825686755877 |
| GO:0001776 | leukocyte homeostasis | 0.0101825686755877 |
| GO:0007242 | intracellular signaling cascade | 0.0101825686755877 |
| GO:0009190 | cyclic nucleotide biosynthetic process | 0.0101825686755877 |
| GO:0048872 | homeostasis of number of cells | 0.0101825686755877 |
| GO:0004428 | inositol or phosphatidylinositol kinase activity | 0.0101825686755877 |
| GO:0007189 | G-protein signaling, adenylate cyclase activating pathway | 0.0122869486827826 |
| GO:0009187 | cyclic nucleotide metabolic process | 0.0125554027972597 |
| GO:0048015 | phosphoinositide-mediated signaling | 0.0139948906204137 |
| GO:0030384 | phosphoinositide metabolic process | 0.0139948906204137 |
| GO:0007188 | G-protein signaling, coupled to cAMP nucleotide second messenger | 0.016860093186008 |
| GO:0006650 | glycerophospholipid metabolic process | 0.016860093186008 |
| GO:0007187 | G-protein signaling, coupled to cyclic nucleotide second messenger | 0.016860093186008 |
| GO:0019933 | cAMP-mediated signaling | 0.0169560597719931 |
| GO:0019935 | cyclic-nucleotide-mediated signaling | 0.0173212513502202 |
| GO:0042113 | B cell activation | 0.0227412066789144 |
| GO:0044445 | cytosolic part | 0.0244981950385326 |
| GO:0006644 | phospholipid metabolic process | 0.0294582099803791 |
| GO:0009165 | nucleotide biosynthetic process | 0.0302212702873356 |
| GO:0043085 | positive regulation of catalytic activity | 0.0323928369149597 |
| GO:0006643 | membrane lipid metabolic process | 0.0350565684588753 |
| GO:0016829 | lyase activity | 0.0350565684588753 |
| GO:0007166 | cell surface receptor linked signal transduction | 0.0374638801911031 |
| GO:0009117 | nucleotide metabolic process | 0.0398981395349427 |
| GO:0046649 | lymphocyte activation | 0.0407661960117566 |
| GO:0055086 | nucleobase, nucleoside and nucleotide metabolic process | 0.040967261749857 |
| GO:0045321 | leukocyte activation | 0.0425994543014596 |
| GO:0001775 | cell activation | 0.0447688215167534 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>
| Ontology term | p-value | n |
|---|---|---|
| lymphoid lineage restricted progenitor cell | 3.30e-12 | 12 |
| T cell | 1.26e-11 | 11 |
| pro-T cell | 1.26e-11 | 11 |
| lymphocyte | 6.39e-11 | 13 |
| common lymphoid progenitor | 6.39e-11 | 13 |
| hematopoietic cell | 1.04e-10 | 32 |
| hematopoietic oligopotent progenitor cell | 1.04e-10 | 32 |
| hematopoietic stem cell | 1.04e-10 | 32 |
| angioblastic mesenchymal cell | 1.04e-10 | 32 |
| hematopoietic multipotent progenitor cell | 1.04e-10 | 32 |
| hematopoietic lineage restricted progenitor cell | 3.07e-10 | 25 |
| mature alpha-beta T cell | 1.51e-09 | 9 |
| alpha-beta T cell | 1.51e-09 | 9 |
| immature T cell | 1.51e-09 | 9 |
| mature T cell | 1.51e-09 | 9 |
| immature alpha-beta T cell | 1.51e-09 | 9 |
| leukocyte | 1.40e-08 | 17 |
| nongranular leukocyte | 1.40e-08 | 17 |
| CD4-positive, alpha-beta T cell | 1.74e-08 | 8 |
| nucleate cell | 4.60e-08 | 16 |
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
| Motifs | -log10(p-value) |
|---|---|
|
{{{tfbs_overrepresentation_jaspar}}} |
